Cortisol increases plasma insulin-like growth factor binding protein-1 in humans

C. A. Conover, G. D. Divertie, Phillip Lee

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Insulin-like growth factor binding protein-1 (IGFBP-1) modulates the metabolic and mitogenic actions of the IGF peptides. Previous studies have stablished insulin as the major regulator of plasma IGFBP-1 in humans, acting to suppress hepatic IGFBP-1 synthesis. In this study, we investigated the regulation of plasma IGFBP-1 by cortisol in humans, independent of insulin. Following an overnight fast, six healthy adult volunteers received a euglycemic pancreatic clamp (somatostatin, 0.12 μg·kg-1·min-1; GH, 3 ng·kg-1·min-1; insulin, 0.05 mU·kg-1·min-1) to block endogenous insulin secretion and to control glucose and plasma hormone concentrations at desired levels. Three hours after the initiation of the pancreatic clamp, each subject received an additional 360 min infusion of either cortisol (2 μg·kg-1·min-1) or saline on separate occasions and in random order. Plasma cortisol concentrations increased from 220 to 970 nmol/l during the cortisol infusion. Insulin concentrations were maintained at approximately 30 pmol/l throughout saline and cortisol infusions. Plasma IGFBP-1 concentrations increased threefold in response to hypoinsulinemia, reaching plateau values of ~140 μg/l with saline infusion. During cortisol infusion, IGFBP-1 levels increased to ~300 μg/l. Over the 360 min study period, the integrated response of plasma IGFBP-1 to cortisol infusion was 314% greater than to saline infusion (p < 0.01). Our data confirm that, under conditions of hypoinsulinemia, cortisol is a significant modulator of plasma IGFBP-1 in humans.

Original languageEnglish (US)
Pages (from-to)140-143
Number of pages4
JournalActa Endocrinologica
Volume128
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Protein 1
Hydrocortisone
Insulin
Glucose Clamp Technique
human IGFBP1 protein
Somatostatin
Healthy Volunteers
Hormones
Glucose
Peptides
Liver

ASJC Scopus subject areas

  • Endocrinology

Cite this

Cortisol increases plasma insulin-like growth factor binding protein-1 in humans. / Conover, C. A.; Divertie, G. D.; Lee, Phillip.

In: Acta Endocrinologica, Vol. 128, No. 2, 1993, p. 140-143.

Research output: Contribution to journalArticle

Conover, C. A. ; Divertie, G. D. ; Lee, Phillip. / Cortisol increases plasma insulin-like growth factor binding protein-1 in humans. In: Acta Endocrinologica. 1993 ; Vol. 128, No. 2. pp. 140-143.
@article{4a6808e6c36f419aae25f77eb6588902,
title = "Cortisol increases plasma insulin-like growth factor binding protein-1 in humans",
abstract = "Insulin-like growth factor binding protein-1 (IGFBP-1) modulates the metabolic and mitogenic actions of the IGF peptides. Previous studies have stablished insulin as the major regulator of plasma IGFBP-1 in humans, acting to suppress hepatic IGFBP-1 synthesis. In this study, we investigated the regulation of plasma IGFBP-1 by cortisol in humans, independent of insulin. Following an overnight fast, six healthy adult volunteers received a euglycemic pancreatic clamp (somatostatin, 0.12 μg·kg-1·min-1; GH, 3 ng·kg-1·min-1; insulin, 0.05 mU·kg-1·min-1) to block endogenous insulin secretion and to control glucose and plasma hormone concentrations at desired levels. Three hours after the initiation of the pancreatic clamp, each subject received an additional 360 min infusion of either cortisol (2 μg·kg-1·min-1) or saline on separate occasions and in random order. Plasma cortisol concentrations increased from 220 to 970 nmol/l during the cortisol infusion. Insulin concentrations were maintained at approximately 30 pmol/l throughout saline and cortisol infusions. Plasma IGFBP-1 concentrations increased threefold in response to hypoinsulinemia, reaching plateau values of ~140 μg/l with saline infusion. During cortisol infusion, IGFBP-1 levels increased to ~300 μg/l. Over the 360 min study period, the integrated response of plasma IGFBP-1 to cortisol infusion was 314{\%} greater than to saline infusion (p < 0.01). Our data confirm that, under conditions of hypoinsulinemia, cortisol is a significant modulator of plasma IGFBP-1 in humans.",
author = "Conover, {C. A.} and Divertie, {G. D.} and Phillip Lee",
year = "1993",
language = "English (US)",
volume = "128",
pages = "140--143",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "2",

}

TY - JOUR

T1 - Cortisol increases plasma insulin-like growth factor binding protein-1 in humans

AU - Conover, C. A.

AU - Divertie, G. D.

AU - Lee, Phillip

PY - 1993

Y1 - 1993

N2 - Insulin-like growth factor binding protein-1 (IGFBP-1) modulates the metabolic and mitogenic actions of the IGF peptides. Previous studies have stablished insulin as the major regulator of plasma IGFBP-1 in humans, acting to suppress hepatic IGFBP-1 synthesis. In this study, we investigated the regulation of plasma IGFBP-1 by cortisol in humans, independent of insulin. Following an overnight fast, six healthy adult volunteers received a euglycemic pancreatic clamp (somatostatin, 0.12 μg·kg-1·min-1; GH, 3 ng·kg-1·min-1; insulin, 0.05 mU·kg-1·min-1) to block endogenous insulin secretion and to control glucose and plasma hormone concentrations at desired levels. Three hours after the initiation of the pancreatic clamp, each subject received an additional 360 min infusion of either cortisol (2 μg·kg-1·min-1) or saline on separate occasions and in random order. Plasma cortisol concentrations increased from 220 to 970 nmol/l during the cortisol infusion. Insulin concentrations were maintained at approximately 30 pmol/l throughout saline and cortisol infusions. Plasma IGFBP-1 concentrations increased threefold in response to hypoinsulinemia, reaching plateau values of ~140 μg/l with saline infusion. During cortisol infusion, IGFBP-1 levels increased to ~300 μg/l. Over the 360 min study period, the integrated response of plasma IGFBP-1 to cortisol infusion was 314% greater than to saline infusion (p < 0.01). Our data confirm that, under conditions of hypoinsulinemia, cortisol is a significant modulator of plasma IGFBP-1 in humans.

AB - Insulin-like growth factor binding protein-1 (IGFBP-1) modulates the metabolic and mitogenic actions of the IGF peptides. Previous studies have stablished insulin as the major regulator of plasma IGFBP-1 in humans, acting to suppress hepatic IGFBP-1 synthesis. In this study, we investigated the regulation of plasma IGFBP-1 by cortisol in humans, independent of insulin. Following an overnight fast, six healthy adult volunteers received a euglycemic pancreatic clamp (somatostatin, 0.12 μg·kg-1·min-1; GH, 3 ng·kg-1·min-1; insulin, 0.05 mU·kg-1·min-1) to block endogenous insulin secretion and to control glucose and plasma hormone concentrations at desired levels. Three hours after the initiation of the pancreatic clamp, each subject received an additional 360 min infusion of either cortisol (2 μg·kg-1·min-1) or saline on separate occasions and in random order. Plasma cortisol concentrations increased from 220 to 970 nmol/l during the cortisol infusion. Insulin concentrations were maintained at approximately 30 pmol/l throughout saline and cortisol infusions. Plasma IGFBP-1 concentrations increased threefold in response to hypoinsulinemia, reaching plateau values of ~140 μg/l with saline infusion. During cortisol infusion, IGFBP-1 levels increased to ~300 μg/l. Over the 360 min study period, the integrated response of plasma IGFBP-1 to cortisol infusion was 314% greater than to saline infusion (p < 0.01). Our data confirm that, under conditions of hypoinsulinemia, cortisol is a significant modulator of plasma IGFBP-1 in humans.

UR - http://www.scopus.com/inward/record.url?scp=0027396969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027396969&partnerID=8YFLogxK

M3 - Article

C2 - 7680833

AN - SCOPUS:0027396969

VL - 128

SP - 140

EP - 143

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 2

ER -